Open AccessThe therapeutic effect of bromocriptine in combination with spironolactone in patients with primary aldosteronism: a hypothesis generating pilot study
Author(s) -
VinCent Wu,
CheHsiung Wu,
Yi Yang,
KuoHow Huang,
ChiaHui Chang,
Shaoyu Yang,
YenHung Lin,
KwanDun Wu
Publication year - 2017
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.20670
Subject(s) - medicine , bromocriptine , spironolactone , primary aldosteronism , oncology , endocrinology , pharmacology , aldosterone , bioinformatics , prolactin , hormone , biology
Dopamine D2-like receptors are attenuated in aldosterone producing adenoma, lead to overproduction of aldosterone in affected patients, and thus reported to serve as a potential treatment target for primary aldosteronism. The D2 dopamine receptor agonist bromocriptine has been used clinically for reducing tumor mass of pituitary adenomas of lactotroph origin. The aim of the present study was to assess the efficacy of adding bromocriptine to spironolactone in the biochemical control of primary aldosteronism.